• 250 participants enrolled in less than five months
• Topline results for NUZ-001 expected in late Q2 CY2027
• Reflects strong recruitment and effective execution
• Participants progressing through the 36-week randomised treatment period

Neurizon Therapeutics Limited has announced the completion of enrolment for Regimen I in the Phase 2/3 HEALEY ALS Platform Trial, evaluating NUZ-001 for amyotrophic lateral sclerosis (ALS). The enrolment, which reached 250 participants in under five months, marks the fastest site activation and completion in the trial's history. This achievement accelerates the anticipated topline efficacy and safety results to late Q2 CY2027. The rapid enrolment reflects strong recruitment and operational efficiencies within the HEALEY ALS Platform Trial network. Participants are now progressing through the 36-week randomised treatment period, with Neurizon focusing on continued execution ahead of the topline readout.

Topline efficacy and safety results for NUZ-001 expected in late Q2 CY2027

Neurizon anticipates delivering topline results for NUZ-001 in late Q2 CY2027, marking an important value inflection point for the company and its shareholders.